Expert Review of Clinical Pharmacology, Год журнала: 2024, Номер 17(11), С. 1081 - 1088
Опубликована: Окт. 25, 2024
Background We aimed to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type diabetes mellitus (T2DM) clinical practice.
Язык: Английский
BMC Women s Health, Год журнала: 2025, Номер 25(1)
Опубликована: Фев. 15, 2025
Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic and hormonal abnormalities. This study aimed to evaluate the comparative efficacy of pharmacological interventions on these outcomes. We conducted systematic review network meta-analysis randomized controlled trials (RCTs) assessing treatments for PCOS. Searches in PubMed, MEDLINE, Embase, Web Science were up October 20, 2023. Eligible studies RCTs at least 12 weeks follow-up outcomes including body weight (BW), mass index (BMI), waist circumference (WC), testosterone, sex hormone-binding globulin (SHBG), lipid profiles, HOMA-IR, fasting blood glucose (FBG), insulin (FINS). Twenty-nine 1476 participants included. The combination standard therapy GLP-1 receptor agonists significantly reduced BW (MD= -3.44; 95% CI= -6.20 -0.67), BMI -2.05; -3.55 -0.55), WC -4.39; -6.75 -2.02) compared alone. Orlistat lowered testosterone (SMD= -2.16; -3.84 -0.48) increased HDL-C levels (SMD = 0.90; CI 0.02 1.79) placebo. also HOMA-IR -1.29; -2.38 -0.21) FBG -1.80; -3.04 -0.55) Combining offers superior improving women effectively reduces androgen levels. These findings support use pharmacotherapy comprehensive management
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Expert Review of Cardiovascular Therapy, Год журнала: 2025, Номер 23(3), С. 65 - 71
Опубликована: Март 4, 2025
Introduction Coronary atherosclerosis, marked by lipid deposition and inflammation, drives cardiovascular morbidity. Traditional treatments focus on reduction, yet newer therapies target plaque composition, aiming to enhance stability prevent coronary events.
Язык: Английский
Процитировано
0
Diabetes Therapy, Год журнала: 2025, Номер unknown
Опубликована: Март 24, 2025
Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, management relied on stepwise medication addition based failures in glucose control. However, benefits and risks combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) sodium-glucose cotransporter inhibitors (SGLT2is) remain inadequately understood. This study conducted scoping review examine available clinical research GLP1-RAs SGLT2is. Additionally, nominal group technique was used gather insights medical experts different areas regarding combined therapy's daily use, concerns, limitations. The followed guidelines outlined Joanna Briggs Institute Reviewer's Manual PRISMA-ScR (Preferred Reporting Items for Systematic Reviews Meta-Analyses Extension Scoping Reviews). final report includes 50 studies. most common designs are observational median (IQR) number patients across studies 355 (1295). Studies reporting metabolic outcomes were common. follow-up time ranges 1.5 60 months. Although limited, evidence seems support agreed that underlying mechanisms appear synergistic rather than antagonistic outcomes. Combining therapy is treatment may occur naturally everyday practice. Limited suggests SGLT2is/GLP1-RAs can potentially improve but not all Quality better-defined paramount guide selection therapy.
Язык: Английский
Процитировано
0
Obesities, Год журнала: 2025, Номер 5(2), С. 26 - 26
Опубликована: Апрель 18, 2025
Obesity represents a global health challenge, with critical and urgent need for long-term, sustainable management strategies. Tirzepatide is novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist. At first approved the treatment of type 2 diabetes mellitus, tirzepatide one latest clinically commercially available pharmacological options obesity management. This narrative review aimed to synthesize existing clinical evidence on efficacy safety in non-diabetic obese individuals. A comprehensive literature search was conducted using PubMed, Scopus, Web Science, ClinicalTrials.gov, Google Scholar databases identify relevant trials, meta-analyses, original studies assessing weight-loss impact from 2022 onwards. Synthesized indicated that achieved up 20.9% weight loss over 72 weeks (SURMOUNT-1), 18.4% after lifestyle intervention (SURMOUNT-3), 17.5% Chinese adults (SURMOUNT-CN), 25.3% continued 88 (SURMOUNT-4). Meta-analyses confirmed higher odds ≥5–20% versus semaglutide liraglutide, significantly reducing body mass index, waist circumference, blood pressure, atherosclerotic cardiovascular disease risk. Health-related quality life improved greater loss, gastrointestinal side effects (nausea, diarrhea, constipation) were common but mild moderate, <5% discontinuation. significant cardiometabolic benefits, individuals, further research needed long-term efficacy, safety, application.
Язык: Английский
Процитировано
0
Gefässchirurgie, Год журнала: 2025, Номер unknown
Опубликована: Апрель 28, 2025
Процитировано
0
Diabetes & Metabolism, Год журнала: 2024, Номер unknown, С. 101594 - 101594
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
2
Expert Review of Clinical Pharmacology, Год журнала: 2024, Номер 17(11), С. 1081 - 1088
Опубликована: Окт. 25, 2024
Background We aimed to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type diabetes mellitus (T2DM) clinical practice.
Язык: Английский
Процитировано
0